BGNE241220P170000
- 2.01
- 0.000.00%
BeiGene Newsroom
Institutions reiterated a "Buy" rating for BEIGENE (06160), being bullish on its strong oncology drug research and development pipeline.
Jefferies Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $286
TD Cowen Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $260
BeiGene (BGNE) Gets a Buy From TD Cowen
JMP Securities Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $288
Jefferies Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $286
Jefferies Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $286
JMP Securities Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $288
Jefferies Maintains BeiGene(BGNE.US) With Buy Rating, Raises Target Price to $286
Morgan Stanley Reaffirms Their Buy Rating on BeiGene (BGNE)
BeiGene Price Target Announced at $300.00/Share by Morgan Stanley
BeiGene Analyst Ratings
Morgan Stanley Assumes BeiGene at Overweight, Announces Price Target of $300
Bernstein Maintains BeiGene(BGNE.US) With Hold Rating, Raises Target Price to $207
Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE) and Teladoc (TDOC)
Research Reports Prospecting丨China Merchants Securities: First gives Beigene a "strong buy" rating, bullish on the rapid increase in sales of products such as Zejula in the short to medium term.
BeiGene (688235): Deeply understanding the field of disease and entering the global competitive stage
Major Bank Rating | bocom intl: Raises beigene target price to 159 HKD, catalysts are about to be densely launched.
Research reports highlight | Soochow Securities: Beigene's growth certainty is relatively high, maintaining a "buy" rating.
BeiGe-U (688235): Overseas sales lead in rapid volume hematoma industry